drugset
Drugs / TQB2868
last change May 2026 re-read 2 minutes ago

TQB2868

Protein / enzyme biologic targets PDCD1 via inhibition

Developed for
triple-negative breast carcinoma · cancer · cervical cancer · female breast carcinoma · hepatocellular carcinoma · hormone receptor-positive breast cancer · pancreatic ductal adenocarcinoma · pancreatic neoplasm
Investigated by
Fudan University · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Trials 7 · a red edge is where a trial was stopped

today NCT07165951 · Ph 3 NCT06441019 · Ph 2 NCT06767813 · Ph 2 NCT05998941 · Ph 2 NCT05749588 · Ph 2 NCT05582499 · Ph 2 NCT05198505 · Ph 1
202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05198505 Apr 2022 → Jun 2023 cancer Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Unknown No outcome recorded
Phase 25 trials
Phase 2 NCT06441019 Jul 2024 → May 2025 hepatocellular carcinoma Fudan University Unknown No outcome recorded
Phase 2 NCT06767813 Mar 2024 → Nov 2026 expected pancreatic neoplasm Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT05998941 Aug 2023 → Feb 2025 cervical cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Withdrawn No outcome recorded
Phase 2 NCT05749588 Mar 2023 → Dec 2027 expected triple-negative breast carcinoma Fudan University Recruiting No outcome recorded
Phase 2 NCT05582499 Nov 2022 → Dec 2027 expected HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma Fudan University Recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT07165951 Dec 2025 → May 2028 expected pancreatic ductal adenocarcinoma Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as TQB2868 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06767813 ↗
6

NCT05198505 ↗

NCT05749588 ↗

NCT07165951 ↗

NCT05582499 ↗

NCT05998941 ↗

NCT06441019 ↗
Action Inhibit “The bifunctional fusion protein targets and neutralizes TGF-β in the tumor microenvironment.” NCT05198505 ↗
Modality Protein / enzyme biologic “TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β” NCT05198505 ↗
Target PDCD1 “TQB2868: an anti-PD-1/TGF-β bispecific antibody in all-comer TNBC” NCT05749588 ↗